Secondary acute myeloid leukemia (AML) is a blood cancer that arises from other blood disorders or previous cancer treatment. Those with secondary AML tend to have a less favorable outlook than ...

Researchers have identified a key weakness in acute myeloid leukemia, offering a promising new strategy to delay the ...

Researchers from the Tumor Profiler consortium have combined single-cell multi-omics and functional profiling for 21 AML ...

Researchers sought to determine whether DNA methylation markers could be helpful in risk stratification for patients with AML and normal cytogenetics.

Molecular approaches applicable at presentation with leukemia support diagnosis, classification, prognostication, stratification and identification of therapeutic targets. Genetic analysis in ...

Acute myeloid leukemia is one of the deadliest cancers. Leukemic stem cells responsible for the disease are highly resistant to treatment. A new editorial paper was published in Oncotarget's ...

A treatment of acute myeloid leukemia being developed by Sanofi (SNY) US Services was granted FDA orphan designation, according to a post to the agency’s website. Published first on TheFly – the ...

Oct. 9, 2024 — Researchers have created a CRISPR-based rapid molecular diagnostic for two forms of leukemia that are driven by mutations that involve gene fusions. The technology accurately ...

In the field of myelodysplastic syndromes (MDS), there are a number of investigational studies designed with the hope of ...

1 A paper by Cronkite 2 (1961) summarizes the natural history of "benzene leukemia ... chromosomes of the first two groups of the Denver classification gave evidence of deletions; polyploidism ...

A new study reveals a modular CAR-T approach that effectively targets heterogeneous antigens in paediatric acute myeloid leukaemia, enhancing treatment success through combinatorial targeting.